BOADICEA, BRCAPRO, Myriad II, IBIS, Penn II, and Manchester models for breast cancers are limited to the utility of predictions for BRCA1 and BRCA2, as they are usually the only genes accounted for in these predictions due to the relatively low frequency of pathogenic mutations in other genes, however, BOADACEA now also provides a pretest probability for ATM, PALB2, and CHEK2 mutations (Lee et al., 2019). The gene discussed is BRCA2; the disease is breast cancer.